1. Home
  2. ZYME vs EEX Comparison

ZYME vs EEX Comparison

Compare ZYME & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • EEX
  • Stock Information
  • Founded
  • ZYME 2003
  • EEX 2013
  • Country
  • ZYME United States
  • EEX United States
  • Employees
  • ZYME N/A
  • EEX N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • EEX Advertising
  • Sector
  • ZYME Health Care
  • EEX Consumer Discretionary
  • Exchange
  • ZYME Nasdaq
  • EEX Nasdaq
  • Market Cap
  • ZYME 846.1M
  • EEX 749.0M
  • IPO Year
  • ZYME 2017
  • EEX 2017
  • Fundamental
  • Price
  • ZYME $11.31
  • EEX $4.69
  • Analyst Decision
  • ZYME Buy
  • EEX Strong Buy
  • Analyst Count
  • ZYME 6
  • EEX 2
  • Target Price
  • ZYME $19.50
  • EEX $7.90
  • AVG Volume (30 Days)
  • ZYME 553.2K
  • EEX 92.7K
  • Earning Date
  • ZYME 05-08-2025
  • EEX 05-01-2025
  • Dividend Yield
  • ZYME N/A
  • EEX 1.28%
  • EPS Growth
  • ZYME N/A
  • EEX N/A
  • EPS
  • ZYME N/A
  • EEX 0.02
  • Revenue
  • ZYME $93,384,000.00
  • EEX $413,100,000.00
  • Revenue This Year
  • ZYME $26.29
  • EEX $14.47
  • Revenue Next Year
  • ZYME $75.78
  • EEX $6.42
  • P/E Ratio
  • ZYME N/A
  • EEX $190.38
  • Revenue Growth
  • ZYME 85.05
  • EEX 4.87
  • 52 Week Low
  • ZYME $8.21
  • EEX $3.22
  • 52 Week High
  • ZYME $17.70
  • EEX $6.74
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 40.96
  • EEX 71.82
  • Support Level
  • ZYME $10.86
  • EEX $4.46
  • Resistance Level
  • ZYME $13.23
  • EEX $4.76
  • Average True Range (ATR)
  • ZYME 0.56
  • EEX 0.17
  • MACD
  • ZYME -0.10
  • EEX 0.10
  • Stochastic Oscillator
  • ZYME 18.78
  • EEX 86.93

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About EEX Emerald Holding Inc.

Emerald Holding Inc is an operator of B2B trade shows in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry, Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. Majority of the revenue for the company is generated from its Connections segment.

Share on Social Networks: